A phase I study of FOLFIRINOX Plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma

Pancreas

Volumn 45, Issue 3, 2016, Pages 370-375

  Ko, Andrew H ^a   LoConte, Noelle ^b   Tempero, Margaret A ^a   Walker, Evan J ^a   Kelley, R Kate ^a   Lewis, Stephanie ^a   Chang, Wei Chou ^c   Kantoff, Emily ^a   Vannier, Michael W ^d   Catenacci, Daniel V ^e   Venook, Alan P ^a   Kindler, Hedy L ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

FOLFIRINOX; Hedgehog; Pancreatic cancer; Phase I; Stroma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PATIDEGIB; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CAMPTOTHECIN; IPI-926; PLATINUM COMPLEX; SONIC HEDGEHOG PROTEIN; VERATRUM ALKALOID;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FEASIBILITY STUDY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEUROLOGIC DISEASE; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CAMPTOTHECIN; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEDGEHOG PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NAUSEA; NERVOUS SYSTEM DISEASES; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VERATRUM ALKALOIDS; VOMITING;

EID: 84959348810     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000458     Document Type: Article

References (30)

1. Ingham PW. Signalling by hedgehog family proteins in Drosophila and vertebrate development. Curr Opin Genet Dev. 1995;5:492-498.
2. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411:349-354.
3. Oro AE, Higgins KM, Hu Z, et al. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276:817-821.
4. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408-1414.
5. Rodriguez-Blanco J, Schilling NS, Tokhunts R, et al. The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 2013;32:2335-2345.
6. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 2011;17: 1504-1508.
7. Thayer SP, diMagliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851-856.
8. Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19:2766-2774.
9. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.
10. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl JMed. 2011;364: 1817-1825.
11. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846-851.
12. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321:1801-1806.
13. Liu MS, Yang PY, Yeh TS. Sonic hedgehog signaling pathway in pancreatic cystic neoplasms and ductal adenocarcinoma. Pancreas. 2007;34:340-346.
14. Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle. 2007;6:1553-1557.
15. Morton JP, Mongeau ME, Klimstra DS, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2007;104:5103-5108.
16. Quint K, Stintzing S, Alinger B, et al. The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology. 2009;9:116-126.
17. Steg A, Vickers SM, Eloubeidi M, et al. Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. Diagn Mol Pathol. 2007;16:229-237.
18. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187-2196.
19. Feldmann G, Fendrich V, McGovern K, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther. 2008;7:2725-2735.
20. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
21. Lee SJ, Lee HK, Cho SY, et al. Identification of osteogenic purmorphamine derivatives. Mol Cells. 2008;26:380-386.
22. Mueller MT, Hermann PC, Witthauer J, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137:1102-1113.
23. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406-410.
24. Infinity Pharmaceuticals company Web site. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle-print&ID=1653550&highlight= Accessed January 27, 2012.
25. Catenacci D, Bahary N, Nattam S, et al. Final analysis of a phase IB/randomized phase II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer: A University of Chicago phase II consortium study [Abstract 4012]. J Clin Oncol. 2013;31(suppl).
26. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735-747.
27. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25:719-734.
28. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl JMed. 2013;369: 1691-1703.
29. de Jesus-Acosta A, O'Dwyer PJ, Ramanathan RK, et al. A phase II study of vismodegib, a hedgehog pathway inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma [Abstract 257]. J Clin Oncol. 2014;32(suppl 3).
30. Van Loon K, Espinoza AM, Fogelman DR, et al. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase ii trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014;43:343-349.